Mesa Laboratories, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MLAB research report →
Range $110 – $110
Price Chart
About the company
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
- CEO
- Siddhartha C. Kadia
- IPO
- 1984
- Employees
- 717
- HQ
- Lakewood, CO, US
Get TickerSpark's AI analysis on MLAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $719.03M
- P/E
- 108.42
- Fwd P/E
- 11.14
- PEG
- 0.17
- P/S
- 2.86
- P/B
- 3.71
- EV/EBITDA
- 17.87
- Div Yield
- 0.50%
- Gross Margin
- 66.58%
- Op Margin
- 10.40%
- Net Margin
- 2.65%
- ROE
- 3.53%
- ROIC
- 3.57%
Latest fiscal year · YoY change
- Revenue
- $249.13M+3.4%
- Gross Profit
- $158.27M+4.9%
- Op Income
- $18.51M
- Net Income
- $6.71M+440.0%
- EPS
- $1.22+438.9%
- OCF Growth
- -8.5%
- FCF Growth
- -6.4%
- 52W High
- $144.35
- 52W Low
- $70.19
- 50D MA
- $130.04
- 200D MA
- $107.68
- Beta
- 1.08
- RSI (14)
- 47
- Avg Volume
- 115.00K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Mesa Labs posted modest Q2 growth and a sharp margin lift, while guiding to a full-year revenue/EBITDA step-up built on restructuring, selective reinvestment, and a more focused clinical genomics business.· November 9, 2026
- Q2 revenue was $62.3 million, up 2.6%; net income was $4.3 million, or $0.75 per diluted share, versus $0.45 a year ago.
- Adjusted EBITDA rose 21.1% to $17.3 million, or 27.8% of sales; gross margin improved to 64.0% from 61.5%.
- Organic growth was 2.6% overall; excluding clinical genomics, revenue growth was about 5% in the quarter and about 3% in the first half.
- SDC grew 14.6% organically and calibration solutions grew about 3.5%, while BPD fell 8.2% organically and clinical genomics fell 8.8%.
- FY27 guidance calls for revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million, with Q3 revenue expected to be about flat year over year mainly due to clinical genomics.
Total revenue for Q2 was $62.3 million, up 2.6% year over year; organic growth was also 2.6% and constant-currency organic growth was 3.1%. Gross profit was $39.9 million, or 64.0% of revenue, up from 61.5% last year. GAAP operating income was $8.4 million, net income was $4.3 million, and EPS was $0.75 versus $0.45 a year ago. Adjusted EBITDA increased 21.1% to $17.3 million, or 27.8% of revenue. For the first half, organic growth was 1.8%, operating cash flow was $18.8 million, capex was $900,000, debt paid down was $20.1 million, and cash ended at $22.3 million with $57.8 million available under the revolver. Management guided FY27 revenue to $250 million-$255 million and adjusted EBITDA to $66 million-$68 million, implying about 5% to 8% EBITDA growth on about 0% to 2% revenue growth versus about $63 million of adjusted EBITDA in FY26. They also said Q3 revenue should be about flat versus last year because clinical genomics will step down, while the other businesses are expected to keep growing.
CEO Siddhartha Kadia framed the quarter as evidence that Mesa’s core franchises are getting stronger, while one business is being reset for profitability. He said sterilization/disinfection control and calibration solutions are the “two steadiest franchises,” and emphasized that clinical genomics is now being managed for cash generation and higher profitability rather than scale. His tone was candid and disciplined: he repeatedly said the company will be judged on the full-year result, not quarter-to-quarter noise, and highlighted a capital allocation framework that favors organic investment, debt reduction, and selective buybacks or tuck-in deals.
CFO John Sakys focused on the financial bridge: revenue of $62.3 million, gross profit of $39.9 million at 64.0% margin, GAAP operating income of $8.4 million, net income of $4.3 million, and adjusted EBITDA of $17.3 million. He noted operating cash flow of $18.8 million in the first half, capex of $900,000, and debt reduction of $20.1 million, leaving $22.3 million in cash and $57.8 million of revolver availability. He also detailed the restructuring, saying total pretax charges are expected to be $2.6 million to $3.4 million net of about $300,000 of stock-comp reversals, with related cash costs of about $2.9 million to $3.7 million. Interest expense fell 25% to $2.1 million, and he said there is a reasonable possibility of a partial release of the U.S. valuation allowance within the next 12 months.
Analysts focused on why second-half guidance implies softer revenue than the first half and whether clinical genomics is becoming a drag on growth. Kadia said the company is not guiding quarter-to-quarter, but that the second half includes the clinical genomics reset, reinvestment ahead of savings, and a tough comparison against a strong Q4 last year when SDC shipped backlog. He also defended keeping clinical genomics in the portfolio by saying the company is now focused on profitable, cash-generating accounts, and pointed to multi-year renewals from the top three customers. In response to questions on China and M&A, he said China growth was driven mainly by other businesses like SDC and parts of BPD, and that SDC/calibration offer more tuck-in opportunities at more reasonable valuations than life sciences tools.
The positive case from this call is that Mesa’s core businesses are growing, margins are improving, and management is actively fixing underperformance. SDC’s delivery issues are said to be largely resolved except for one remaining product line, and clinical genomics is being reset in a way management expects will boost profitability and cash generation. The company is also paying down debt, adding a share repurchase authorization, and targeting higher adjusted EBITDA growth than revenue growth for the full year.
The main risks are that the second half depends on a clinical genomics reset and a still-incomplete fix in one key SDC product line, so revenue may remain uneven. BPD had a weak quarter due to export-control delays and shipments slipping into the third quarter, and management acknowledged that Q3 revenue should be about flat year over year because of the clinical genomics step-down. The restructuring also signals that clinical genomics has been a long-term revenue drag, with lower revenue expected going forward even if margins improve.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.4%
- Shares Outstanding
- 5.62M
- Float Shares
- 4.97M
of shares held by institutions
161 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Long Path Partners LP | 480.17K | ▲ 3.04K |
| Blackrock, Inc. | 457.60K | ▲ 17.05K |
| Wasatch Advisors LP | 387.13K | ▲ 271.46K |
| Vanguard Group Inc | 321.90K | ▲ 182 |
| Victory Capital Management Inc | 276.56K | ▲ 276.56K |
| Vanguard Capital Management LLC | 236.21K | ▼ 1.24K |
| Raymond James Financial Inc | 175.08K | ▲ 25.14K |
| Arrowstreet Capital, Limited Partnership | 173.23K | ▲ 173.23K |
| Geode Capital Management, LLC | 165.74K | ▲ 26.05K |
| Dimensional Fund Advisors LP | 163.91K | ▲ 15.51K |
| Jacobs Levy Equity Management, Inc | 145.57K | ▲ 14.73K |
| Kennedy Capital Management LLC | 143.20K | ▲ 4.90K |
Held by 204 ETFs
Biggest fund positions in MLAB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 27 | Shah Sanket | other | 0 |
| Nov 10, 27 | Shah Sanket | other | 0 |
| Oct 13, 26 | Sullivan John James | other | 1,200 |
| Sep 9, 26 | Capone Mark Christopher | other | 2,423 |
| Sep 9, 26 | Ladiwala Shiraz Shabanali | other | 2,510 |
| Sep 9, 09 | Alltoft Jennifer Sadie | other | 1,774 |
| Sep 9, 26 | Hall Shannon | other | 1,774 |
| Sep 9, 26 | Sullivan John James | other | 1,774 |
| Sep 9, 26 | Tripeny R Tony | other | 1,774 |
| Aug 15, 26 | Capone Mark Christopher | other | 2,784 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MLAB coverage
Recent articles, reports, and earnings notes.
No research on MLAB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MLAB report →Mesa Laboratories, Inc. (MLAB) Q2 2027 Earnings Call Transcript
seekingalpha.com · Nov 10
What Mesa Laboratories (MLAB) Said on Its Q2 Earnings Call
marketbeat.com · Nov 9
Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance
globenewswire.com · Nov 9
Mesa Labs Announces Second Quarter Financial Results Release Date and Earnings Conference Call
globenewswire.com · Oct 28
Diamond Hill Small Cap Fund Q3 2026 Portfolio Activity
seekingalpha.com · Oct 28
Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth
globenewswire.com · Oct 13
Mesa Laboratories (NASDAQ:MLAB) Hits New 12-Month High – Should You Buy?
defenseworld.net · Oct 7
Mesa Laboratories Inc (MLAB) Shares Surge 4.1% -- What GF Score of 75 Tells Investors
gurufocus.com · Sep 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.